Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 7/20 | 0.56 |
| ▸ | ROS1 | P08922 | 3/20 | 0.56 |
| ▸ | MET | P08581 | 1/20 | 0.56 |
| ▸ | FLT3 | P36888 | 2/20 | 0.55 |
| ▸ | EGFR | P00533 | 13/20 | 0.54 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1035643 | 0.91 | GLO1 (0.57) | ALKROS1METFLT3EGFR | |
| SCHEMBL1075655 | 0.91 | EGFR (0.57) | ALKROS1METFLT3EGFR | |
| SCHEMBL13695252 | 0.90 | BRD4 (0.51) | ALKROS1METEGFR | |
| SCHEMBL1035875 | 0.87 | ZAP70 (0.61) | ALKROS1METFLT3EGFR | |
| SCHEMBL1038670 | 0.86 | AXL (0.63) | ALKROS1METFLT3EGFR | |
| SCHEMBL1038446 | 0.85 | ALK (0.63) | ALKROS1METFLT3EGFR | |
| SCHEMBL12726508 | 0.84 | ALK (0.62) | ALKROS1METFLT3EGFR | |
| SCHEMBL1035566 | 0.83 | EGFR (0.60) | ALKROS1METFLT3EGFR | |
| SCHEMBL1037400 | 0.81 | ALK (0.56) | ALKROS1METFLT3EGFR | |
| SCHEMBL12726512 | 0.81 | ALK (0.63) | ALKROS1METFLT3EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110098288-A1 | SULFONAMIDES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2011-04-28 | — | — | US | claimed |
| EP-2276747-A1 | SULFONAMIDES AS ZAP-70 INHIBITORS | Cellzome Limited (GB) | 2011-01-26 | — | — | EP | claimed |
| WO-2009112490-A1 | SULFONAMIDES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2009-09-17 | — | — | WO | claimed |
| US-20110098288-A1 | SULFONAMIDES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2011-04-28 | — | — | US | disclosed |
| US-20110098288-A1 | SULFONAMIDES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2011-04-28 | — | — | US | disclosed |
| EP-2276747-A1 | SULFONAMIDES AS ZAP-70 INHIBITORS | Cellzome Limited (GB) | 2011-01-26 | — | — | EP | disclosed |
| WO-2009112490-A1 | SULFONAMIDES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2009-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098288-A1 | SULFONAMIDES AS ZAP-70 INHIBITORS | ZAP70, SYK, LCK | ALK 846/4885ROS1 1148/4885MET 4613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.